This is the authors' abstract. We don't add key points for this paper.
We deleted subunits I ( cydA ) and II ( cydB ) of the Mycobacterium tuberculosis cytochrome bd menaquinol oxidase. The resulting Δ cydA and Δ cydAB mutants were hypersusceptible to compounds targeting the mycobacterial bc 1 menaquinol-cytochrome c oxidoreductase and exhibited bioenergetic profiles indistinguishable from strains deficient in the ABC-type transporter, CydDC, predicted to be essential for cytochrome bd assembly. These results confirm CydAB and CydDC as potential targets for drugs aimed at inhibiting a terminal respiratory oxidase implicated in pathogenesis.
No takes yet. Share an insight, caveat, or question.
Lamprecht et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: